As Washington lawmakers struggle to find ways to lower drug costs, a new survey finds that a sizable proportion of employers support proposals to eliminate the rebates paid by drug makers to win favorable insurance coverage.

Specifically, 42% of nearly 600 employers support eliminating rebates for both public and private payers, and another 5% were in favor of eliminating them only for government healthcare plans.  Just 17% opposed any change to the current rebating system, but 36% have no opinion or want more information, according to the survey conducted last month by the Mercer benefits consulting firm.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy